Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe.
作者信息
Merkel C, Whicher C H, Bomanji J, Herrmann K, Ćwikła J, Jervis N, Wait S, Chiti A
机构信息
The Health Policy Partnership, London, UK.
Institute of Nuclear Medicine UCLH NHS Foundation Trust, London, UK.
出版信息
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1335-1339. doi: 10.1007/s00259-020-04745-7.
Abstract
摘要
相似文献
1
Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe.实现放射性配体疗法的潜力：欧洲实施障碍的政策解决方案。
Eur J Nucl Med Mol Imaging. 2020 Jun;47(6):1335-1339. doi: 10.1007/s00259-020-04745-7.
2
The perception of barriers concerning opioid medicines: A survey examining differences between policy makers, healthcare professionals and other stakeholders.对阿片类药物相关障碍的认知：一项调查政策制定者、医疗保健专业人员和其他利益相关者之间差异的研究。
Palliat Med. 2020 Apr;34(4):493-503. doi: 10.1177/0269216319894190. Epub 2019 Dec 23.
3
A Systematic Content Analysis of Policy Barriers Impeding Access to Opioid Medication in Central and Eastern Europe: Results of ATOME.中东欧地区获取阿片类药物的政策障碍的系统内容分析：ATOME研究结果
J Pain Symptom Manage. 2016 Jan;51(1):99-107. doi: 10.1016/j.jpainsymman.2015.08.012. Epub 2015 Sep 18.
4
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.长效注射用抗逆转录病毒疗法治疗艾滋病毒感染者的最佳实施的多层次考量：参与3期试验的医疗服务提供者的观点
BMC Health Serv Res. 2021 Mar 20;21(1):255. doi: 10.1186/s12913-021-06214-9.
5
HIV policy implementation in two health and demographic surveillance sites in Uganda: findings from a national policy review, health facility surveys and key informant interviews.乌干达两个健康与人口监测点的艾滋病病毒政策实施情况：一项国家政策审查、医疗机构调查及关键信息提供者访谈的结果
Implement Sci. 2017 Apr 5;12(1):47. doi: 10.1186/s13012-017-0574-z.
6
The Palliative Care Challenge: Analysis of Barriers and Opportunities to Integrate Palliative Care in Europe in the View of National Associations.姑息治疗挑战：从各国协会视角分析欧洲姑息治疗整合的障碍与机遇
J Palliat Med. 2017 Nov;20(11):1195-1204. doi: 10.1089/jpm.2017.0039. Epub 2017 May 16.
7
Child and adolescent health in Europe: monitoring implementation of policies and provision of services.欧洲儿童和青少年健康：监测政策执行和服务提供情况。
Lancet Child Adolesc Health. 2018 Dec;2(12):891-904. doi: 10.1016/S2352-4642(18)30286-4. Epub 2018 Nov 1.
8
Plus ça change, plus c'est la même chose: a Review of Recent Alcohol Policy Developments in Europe.万变不离其宗：欧洲近期酒精政策发展综述
Alcohol Alcohol. 2019 Mar 1;54(2):123-127. doi: 10.1093/alcalc/agz013.
9
Clinical priorities, barriers and solutions in end-of-life cancer care research across Europe. Report from a workshop.欧洲终末期癌症关怀研究的临床重点、障碍和解决方案。研讨会报告。
Eur J Cancer. 2010 Jul;46(10):1815-22. doi: 10.1016/j.ejca.2010.03.012. Epub 2010 Apr 22.
10
Tinnitus healthcare: a survey revealing extensive variation in opinion and practices across Europe.耳鸣保健：一项揭示欧洲各国意见和实践广泛差异的调查。
BMJ Open. 2020 Jan 21;10(1):e029346. doi: 10.1136/bmjopen-2019-029346.
引用本文的文献
1
Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group.优化胃肠胰神经内分泌肿瘤患者的放射性配体治疗：来自意大利多学科专家组的专家意见。
Adv Ther. 2024 Jan;41(1):113-129. doi: 10.1007/s12325-023-02714-8. Epub 2023 Nov 21.
2
Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.开拓先进前列腺癌治疗的新领域：探索前列腺特异性膜抗原靶向纳米医学联合治疗的潜力。
Front Immunol. 2023 Sep 19;14:1265751. doi: 10.3389/fimmu.2023.1265751. eCollection 2023.
3
Radioligand therapies in cancer: mapping the educational landscape in Europe.癌症的放射性配体疗法：绘制欧洲的教育图谱。
Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2692-2698. doi: 10.1007/s00259-023-06217-0. Epub 2023 Apr 14.
4
Commercial and business aspects of alpha radioligand therapeutics.α放射性配体疗法的商业和业务方面。
Front Med (Lausanne). 2023 Feb 2;9:1070497. doi: 10.3389/fmed.2022.1070497. eCollection 2022.
5
Lu-PSMA-RLT of metastatic castration-resistant prostate cancer: limitations and improvements.转移性去势抵抗性前列腺癌的 Lu-PSMA-RLT：局限性与改进。
Ann Nucl Med. 2021 Aug;35(8):861-870. doi: 10.1007/s12149-021-01649-w. Epub 2021 Jun 27.
本文引用的文献
1
A Care Process Model to Deliver Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors.一种为神经内分泌肿瘤患者提供镥-奥曲肽肽受体放射性核素治疗的护理流程模型。
Front Oncol. 2019 Jan 9;8:663. doi: 10.3389/fonc.2018.00663. eCollection 2018.
2
Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.靶向 α 治疗，一类新兴的癌症治疗药物：综述。
JAMA Oncol. 2018 Dec 1;4(12):1765-1772. doi: 10.1001/jamaoncol.2018.4044.
3
Guidance on Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division.基于单核医学科经验的镥- DOTATATE肽受体放射性核素治疗指南。
J Nucl Med Technol. 2018 Sep;46(3):237-244. doi: 10.2967/jnmt.118.209148. Epub 2018 Aug 3.
4
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With Lu-Dotatate in the Phase III NETTER-1 Trial.在 III 期 NETTER-1 试验中，接受 Lu-Dotatate 治疗的进展性中肠神经内分泌肿瘤患者的生活质量与健康相关。
J Clin Oncol. 2018 Sep 1;36(25):2578-2584. doi: 10.1200/JCO.2018.78.5865. Epub 2018 Jun 7.
5
PSMA Theranostics: Current Status and Future Directions.前列腺特异性膜抗原诊疗学：现状与未来方向
Mol Imaging. 2018 Jan-Dec;17:1536012118776068. doi: 10.1177/1536012118776068.
6
Results and adverse events of personalized peptide receptor radionuclide therapy with Yttrium and Lutetium in 1048 patients with neuroendocrine neoplasms.1048例神经内分泌肿瘤患者接受钇和镥个体化肽受体放射性核素治疗的结果及不良事件
Oncotarget. 2018 Feb 15;9(24):16932-16950. doi: 10.18632/oncotarget.24524. eCollection 2018 Mar 30.
7
Recent advances in theranostics and challenges for the future.治疗诊断学的最新进展与未来挑战。
Br J Radiol. 2018 Nov;91(1091):20170893. doi: 10.1259/bjr.20170893. Epub 2018 Mar 29.
8
Current status of theranostics in prostate cancer.前列腺癌治疗学的现状。
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):471-495. doi: 10.1007/s00259-017-3882-2. Epub 2017 Dec 28.
9
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer.镭-223治疗转移性去势抵抗性前列腺癌的实用建议。
Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1671-1678. doi: 10.1007/s00259-017-3756-7. Epub 2017 Jun 19.
10
Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment.靶向放射性核素治疗：向精准癌症治疗的演进
AJR Am J Roentgenol. 2017 Aug;209(2):277-288. doi: 10.2214/AJR.17.18264. Epub 2017 May 2.
Zotero 插件